MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

105.25

-0.38%↓

WBA

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

105.25

-0.38%↓

WBA

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

105.25

-0.38%↓

WBA

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

105.25

-0.38%↓

WBA

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

105.25

-0.38%↓

WBA

+0.36%↑

CHE

545.53

-2.68%↓

Начало・Списък с акции・Amicus Therapeutics Inc

Amicus Therapeutics Inc

Отворен

СекторЗдравеопазване

7.3 2.1

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

7.02

Максимум

7.33

Ключови измерители
By Trading Economics
Приходи	21M 15M
Продажби	8.2M 150M
EPS	0.09
Марж на печалбата	9.845
Служители	499
EBITDA	286K 22M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+120.28% upside

Дивиденти
By Dow Jones
Следващи печалби	1.05.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-795M 2.1B
Предишно отваряне	5.2
Предишно затваряне	7.3

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

6.71 / 7.25 Подкрепа & съпротива

Amicus Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.04.2025 г., 23:54 ч. UTC

Горещи акции

Stocks to Watch: Alphabet, Intel, AppFolio

24.04.2025 г., 23:51 ч. UTC

Пазарно говорене

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24.04.2025 г., 23:46 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

24.04.2025 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24.04.2025 г., 23:37 ч. UTC

Топ новини

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24.04.2025 г., 23:36 ч. UTC

Топ новини

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24.04.2025 г., 23:13 ч. UTC

Топ новини

Печалби

Google's Earnings Power Holds Up in Global Turbulence -- Update

24.04.2025 г., 23:09 ч. UTC

Топ новини

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24.04.2025 г., 23:02 ч. UTC

Придобивния, сливания и поглъщания

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24.04.2025 г., 23:02 ч. UTC

Придобивния, сливания и поглъщания

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24.04.2025 г., 22:51 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24.04.2025 г., 22:48 ч. UTC

Топ новини

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24.04.2025 г., 22:47 ч. UTC

Пазарно говорене

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24.04.2025 г., 22:38 ч. UTC

Пазарно говорене

Печалби

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24.04.2025 г., 22:24 ч. UTC

Печалби

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24.04.2025 г., 22:24 ч. UTC

Печалби

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24.04.2025 г., 22:24 ч. UTC

Пазарно говорене

Печалби

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24.04.2025 г., 22:23 ч. UTC

Печалби

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24.04.2025 г., 22:11 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

24.04.2025 г., 22:11 ч. UTC

Пазарно говорене

Печалби

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24.04.2025 г., 22:09 ч. UTC

Топ новини

Печалби

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24.04.2025 г., 22:00 ч. UTC

Пазарно говорене

Печалби

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24.04.2025 г., 21:39 ч. UTC

Топ новини

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24.04.2025 г., 21:24 ч. UTC

Топ новини

Печалби

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24.04.2025 г., 21:24 ч. UTC

Топ новини

Печалби

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24.04.2025 г., 21:23 ч. UTC

Топ новини

Печалби

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24.04.2025 г., 21:04 ч. UTC

Печалби

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24.04.2025 г., 21:03 ч. UTC

Печалби

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24.04.2025 г., 21:03 ч. UTC

Печалби

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24.04.2025 г., 21:02 ч. UTC

Печалби

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Сравнение с други в отрасъла

Ценова промяна

Amicus Therapeutics Inc Прогноза

Ценова цел

By TipRanks

120.28% нагоре

12-месечна прогноза

Среден 15.86 USD 120.28%

Висок 20 USD

Нисък 12 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Amicus Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Amicus Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

6.71 / 7.25Подкрепа & съпротива

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.